Drugs / NmCV-5
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03295318 | Nov 2017 → Aug 2018 | meningococcal meningitis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04358731 | Dec 2019 → Mar 2021 | meningococcal infection | Serum Institute of India Pvt. Ltd. | Completed | Met primary |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT05093829 | Mar 2022 → Mar 2023 | meningococcal meningitis | Emory University | Completed | Met primary |
| Phase 3 | NCT03964012 | Aug 2019 → Feb 2020 | meningococcal meningitis | Serum Institute of India Pvt. Ltd. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NmCV-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03295318 ↗ |
| Modality | Vaccine | “Pentavalent Meningococcal Vaccine (NmCV-5)” NCT03964012 ↗ |
| Route | Intramuscular | “Vaccinations were administered intramuscularly in the deltoid muscle.” PMID 39521012 ↗ Nov 2024 |